Moss B, Carroll M W, Wyatt L S, Bennink J R, Hirsch V M, Goldstein S, Elkins W R, Fuerst T R, Lifson J D, Piatak M, Restifo N P, Overwijk W, Chamberlain R, Rosenberg S A, Sutter G
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Adv Exp Med Biol. 1996;397:7-13. doi: 10.1007/978-1-4899-1382-1_2.
Three model systems were used to demonstrate the immunogenicity of highly attenuated and replication-defective recombinant MVA. (1) Intramuscular inoculation of MVA-IN-Fha/np induced humoral and cell-mediated immune responses in mice and protectively immunized them against a lethal respiratory challenge with influenza virus. Intranasal vaccination was also protective, although higher doses were needed. (2) In rhesus macaques, an immunization scheme involving intramuscular injections of MVA-SIVenv/gag/pol greatly reduced the severity of disease caused by an SIV challenge. (3) In a murine cancer model, immunization with MVA-beta gal prevented the establishment of tumor metastases and even prolonged life in animals with established tumors. These results, together with previous data on the safety of MVA in humans, suggest the potential usefulness of recombinant MVA for prophylactic vaccination and therapeutic treatment of infectious diseases and cancer.
使用三种模型系统来证明高度减毒且复制缺陷的重组痘苗病毒 Ankara（MVA）的免疫原性。（1）肌肉注射 MVA-IN-Fha/np 可在小鼠中诱导体液免疫和细胞介导的免疫反应，并对其进行保护性免疫，使其免受流感病毒致死性呼吸道攻击。鼻内接种也具有保护作用，尽管需要更高剂量。（2）在恒河猴中，涉及肌肉注射 MVA-SIVenv/gag/pol 的免疫方案大大降低了由猴免疫缺陷病毒（SIV）攻击引起的疾病严重程度。（3）在小鼠癌症模型中，用 MVA-β半乳糖苷酶免疫可防止肿瘤转移的形成，甚至延长已形成肿瘤的动物的寿命。这些结果，连同先前关于 MVA 在人类中的安全性数据，表明重组 MVA 在预防接种和治疗传染病及癌症方面具有潜在用途。
